FIGURE

Fig. 1

ID

ZDB-FIG-250421-100

Publication

Treis et al., 2025 - Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

Combined treatment with SL-176 and GSK-J4 induces synergistic cytotoxicity in neuroblastoma cells.

Waterfall plots showing the compounds with the highest differential drug sensitivity score (ΔDSS) in combination with SL-176 as compared to vehicle in IMR-32 cells (A) and SK-N-AS cells (B). Dashed lines indicate ΔDSS = 5, the level considered as cut-off for plausible synergy detected through this assay. Combinations with ΔDSS ≥ 3 are shown. Colors indicate drug classes and # indicates suspected false positives. C Dose-response curves for GSK-J4 in IMR-32 and SK-N-AS cells in combination with either vehicle or fixed-dose SL-176 (11 µM). Addition of SL-176 shifted the GSK-J4 dose-response curve one order of magnitude to the left. D Morphology of IMR-32 cells treated for 72 hours either with vehicle, SL-176 (3 µM), GSK-J4 (0.3 µM) or the combination. Dose-response curves (E), dose-response matrices (F) and synergy landscapes (G) for four different neuroblastoma cell lines with different genetic characteristics, treated with GSK-J4+/– SL-176. Dose response data shown is the mean of at least three independent experiments from WST-1. Synergy was assessed with the ZIP method using the SynergyFinder tool. H δ scores of the areas with the most synergistic dose combinations of SL-176 and GSK-J4 for eight neuroblastoma cell lines and human dermal fibroblasts (nHDF). I combining GSK-J4 treatment (0.3 µM for SK-N-SH and 0.1 µM for SK-N-BE(2)) with siRNA-knockdown of PPM1D yielded significantly lower cell confluency after 72 hours for two out of three constructs for each cell line (One-way ANOVA with Dunnett’s post-test, SK-N-SH: neg. siRNA+GSK-J4 vs siPPM1D1 P = 0.00496, neg. siRNA+GSK-J4 vs siPPM1D2 P = 0.0055 and SK-N-BE(2): neg. siRNA+GSK-J4 vs siPPM1D1 P = 0.0016, neg. siRNA+GSK-J4 vs siPPM1D2 P = 0.0387). Mean ± SD for four (SK-N-SH) or three (SK-N-BE(2)) independent experiments, performed in triplicates. Knockdown was confirmed to be significant at 60-72% remaining PPM1D expression for SK-N-SH and 11-44% remaining PPM1D expression for SK-N-BE(2).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Dis.